-
Through license out, ADC drugs are speeding up to the sea!
Time of Update: 2022-08-15
In May of this year, Kelun Pharmaceutical announced a paid exclusive license to Merck to develop, manufacture and commercialize the ADC drug SKB-264 targeting TROP2 outside China (including mainland China, Hong Kong, Macau and Taiwan) .
-
The innovative drug track is popular, and the enthusiasm for financing of pharmaceutical companies continues to rise
Time of Update: 2022-08-15
The clinical advancement of multiple core pipelines marks the full-speed advancement of Tongyi Medicine's R&D pipeline in the dual-ligand drug coupling technology platform (Bi-XDC) According to the announcement, the financing funds will be mainly used for the clinical development of Tongyi Bi-XDC pipeline, including CBP-1008 China key registration phase II clinical trial, CBP-1018 China-US clinical phase I/II trial, CBP-1019 China-US clinical trial Phase I clinical trials, CBP-8088 (C-PROTAC) Sino-US IND application, etc.
-
Announcement of pharmaceutical companies listed on the Shenzhen Stock Exchange in August and October: a large number of pharmaceutical companies such as Huadong Medicine and Xinlitai disclose their semi-annual reports
Time of Update: 2022-08-15
Huadong Medicine announced on the same day that the company's wholly-owned subsidiary Zhongmei Huadong will invest no more than 396 million yuan in total to obtain 60% of Huaren Technology by way of capital increase and transfer of shares.
-
Within a week, many pharmaceutical companies have reported reviews, including Shanghai Pharmaceuticals, Zhejiang Pharmaceuticals, etc.
Time of Update: 2022-08-15
. Shanghai Pharmaceuticals: Folic Acid Tablets Passed Consistency Evaluation of Generic Drugs Shanghai Pharmaceuticals announced on August 4 that Changzhou Pharmaceutical Factory, a subsidiary of the company, recently received the "Approval Notice for Supplementary Drug Application" issued by the State Food and Drug Administration.
-
All in one article to cover the opportunity of Chinese patent medicine project!
Time of Update: 2022-08-15
2 New improved traditional Chinese medicine: looking for different ways of using drugs to improve the project New improved traditional Chinese medicine drugs, namely Class 2 traditional Chinese medicines, refer to preparations that change the route of administration and dosage form of traditional Chinese medicines already on the market, and have clinical application advantages and characteristics, or increase functions and indications; they are further subdivided into 2.
-
Industry: The Chinese herbal medicine market may gradually become polarized in the future
Time of Update: 2022-08-15
In the old version, only ginseng, licorice, astragalus and other varieties stipulated the limit standards for 9-22 kinds of organochlorine pesticide residues, while the new version of the pharmacopoeia for heavy metals and banned pesticides The general requirements for the plant medicinal materials included in the pharmacopoeia have reached the standard.
-
Pharmaceutical companies start a wave of coaching changes, and another chairman resigns!
Time of Update: 2022-08-15
Recently, China Resources Shuanghe announced that Mr. Feng Yi, the chairman of the company, will no longer serve as a director, chairman and chairman of the strategy committee of the company's ninth board of directors since May 11, 2022 because he has reached the statutory retirement age .
-
Inventory of new drug clinical applications in the first half of the year: anti-tumor drugs are the most popular, the field of diabetes is popular, and the "top three" companies prefer to declare
Time of Update: 2022-08-15
Anticancer drugs are still the hottest From the perspective of drug types, the new drugs applied for clinical use are mainly chemical drugs, with a total of 464, accounting for about 59%; the biological products for therapeutic use are closely followed, with a total of 283, accounting for about 36%; the number of Chinese patent medicines is still small.
-
The seventh batch of successful bidders for centralized procurement "successfully won", and the price is close to the cost?
Time of Update: 2022-08-15
For the sample of auxiliary materials corresponding to the winning bidders listed in the application form 1 (non-bidding companies can also apply) , a maximum of 5000g of samples will be provided at one time according to different types of discounts!
-
Domestic EGFR inhibitors "kill" intensified!
Time of Update: 2022-08-15
Today, the focus of competition in the market is mainly on the third-generation EGFR inhibitors—— Domestic third-generation EGFR-TKI market Data sources: corporate announcements, public information collation AstraZeneca Osimertinib: Three indications have been approved in China, two of which are covered by medical insurance, and the price has dropped from 51,000 yuan/box/month to the highest reimbursement by medical insurance, and the patient is only responsible for 1,674 yuan/box/month .
-
200 first generic drugs will be approved!
Time of Update: 2022-08-15
. Table 2: Top 10 products that are popular for imitation listings Figure 1: Global and domestic sales of the three major products in 2021 In 2017, Novartis' sacubitril and valsartan sodium tablets were approved for import, and in 2019, they entered the national medical insurance negotiation catalog and their sales increased rapidly In 2021, the total sales of Chinese public medical institution terminals, Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals will exceed 2 billion yuan.
-
New perspectives, new ideas!
Time of Update: 2022-08-15
. Topic: Three-dimensional naturalized ecological restoration technology of river corridors Zhang Jing, senior engineer at the Institute of Water Ecology and Environment, China Academy of Water Resources and Hydropower, Deputy Secretary-General of the Eco-Hydraulic Engineering Special Committee of the China Hydraulic Society Open and dynamic, river corridors include floodplains, highland edge transition zones, and river troughs in cross-section.
-
Traditional Chinese Medicine: A protracted battle against greed, the key to victory is "the easiest"
Time of Update: 2022-08-15
It is the root cause of the good quality trend of traditional Chinese medicine products From the national drug sampling inspection annual reports over the years, we can find out the reason for the fundamental change in the qualification rate of Chinese herbal medicines.
-
13 Class 1 innovative drugs have been approved for marketing!
Time of Update: 2022-08-15
Acceptance in the first half of 2022 According to the latest statistics from Yaozhi data, from January to June 2022, CDE has undertaken a total of 5,850 new drug registration applications (counted by acceptance number, except for review, the same below), including 4,139 for chemical drugs, 740 for traditional Chinese medicine, and 740 for biological products.
-
The State Food and Drug Administration held a meeting to deploy and deepen the special rectification of drug safety
Time of Update: 2022-08-15
The meeting emphasized that it is necessary to fully implement the spirit of General Secretary Xi Jinping's important instructions, in accordance with the deployment requirements of the first meeting of the State Council's leading group to focus on cracking down on crimes that endanger drug safety, and adhere to the combination of severely cracking down on crimes and strengthening daily supervision and improving long-term mechanisms.
-
This field of rare diseases has ushered in new treatment options, which are independently developed by domestic pharmaceutical companies!
Time of Update: 2022-08-15
. Recently, there is good news that ABSK021, a highly selective CSF-1R inhibitor independently developed by Heyu Pharma, has been recognized by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China as a breakthrough therapy drug for the treatment of inoperable tenosynovial giant cells.
-
my country has initially formed online and offline integrated medical services, and the country has issued detailed rules to "escort"
Time of Update: 2022-08-15
. In order to standardize the behavior of Internet diagnosis and treatment, the National Health Commission and the State Administration of Traditional Chinese Medicine recently issued the "Internet Diagnosis and Treatment Supervision Rules (Trial)", requiring that the diagnosis and treatment behaviors that occur on the Internet must rely on physical medical institutions to conduct online medical treatment.
-
Levosalbutamol hydrochloride nebulized inhalation solution soared by 3209%!
Time of Update: 2022-08-15
Figure 2: Sales of levalbuterol hydrochloride atomized inhalation solution at terminals in public medical institutions in China (unit: 10,000 yuan)Source: Minet.
Figure 2: Sales of levalbuterol hydrochloride atomized inhalation solution at terminals in public medical institutions in China (unit: 10,000 yuan)Source: Minet.
-
The gourd baby who focuses on children's medicine needs to pay attention to the market changes of Forsythia zhimu!
Time of Update: 2022-08-15
Huluwa Pharmaceutical Focuses on Children's Proprietary Chinese Medicine Huluwa Pharmaceutical has seized the business core of paediatric drugs, and has 34 varieties of paediatric drugs in production and sales in the field of paediatric drugs (all of which have clear usage and dosage for children), Including Pediatric Feire Kechuan Granules, Changyanning Granules/Capsules, Cefixime Dispersible Tablets, Pediatric Paracetamol Huangnamin Granules, Pediatric Cough Syrup, Pediatric Qingyan Granules, etc.
-
In the 100 billion chemical drug market, a new class of drugs is about to emerge
Time of Update: 2022-08-15
power to gain more market According to the industry, from the perspective of pharmaceutical companies accelerating the R&D and innovation of chemical drugs, China's chemical pharmaceutical preparation industry has entered a stage of rapid differentiation, structural upgrading, and elimination of outdated production capacity.
